INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results